Drug Profile
SEP 227162
Alternative Names: SEP-227162; SEP-227164Latest Information Update: 21 May 2010
Price :
$50
*
At a glance
- Originator Sepracor
- Developer Dainippon Sumitomo Pharma; Sepracor
- Class Antidepressants
- Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 21 May 2010 Discontinued - Phase-II for Depression in USA (unspecified route)
- 05 Nov 2009 Clinical development is ongoing in USA
- 20 Oct 2009 Sepracor has been acquired by Dainippon Sumitomo Pharma